- Home
- EYPT vs BLKB Comparison
EYPT vs BLKB Comparison
Compare EYPT & BLKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | BLKB |
|---|---|---|
| Founded | 1987 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Computer Software: Prepackaged Software |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2005 | 2004 |
Fundamental Metrics
Financial Performance| Metric | EYPT | BLKB |
|---|---|---|
| Price | $11.92 | $42.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | $31.80 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 1.5M | 608.0K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 142.32 |
| EPS | N/A | ★ 0.67 |
| Revenue | ★ $7,539,000.00 | N/A |
| Revenue This Year | N/A | $6.26 |
| Revenue Next Year | $3,115.57 | $4.25 |
| P/E Ratio | ★ N/A | $53.45 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.41 | $25.58 |
| 52 Week High | $19.11 | $70.94 |
Technical Indicators
Market Signals| Indicator | EYPT | BLKB |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 80.48 |
| Support Level | $9.65 | $34.65 |
| Resistance Level | $13.32 | $64.76 |
| Average True Range (ATR) | 0.81 | 2.08 |
| MACD | -0.23 | 1.04 |
| Stochastic Oscillator | 3.24 | 97.23 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.